Pancreatic Cancer Research

ResearcherUniversity of IowaActive in the last 2 years

Juan Du

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3444-5043; OpenAlex author ID A5100697923. Sources: OpenAlex.

Their work

Papers
20
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 20

  1. Potentiating the effect of immunotherapy in pancreatic cancer using gas-entrapping materials. Co-author DOI 10.1016/j.biomaterials.2025.123097↗
  2. Pharmacologic Ascorbate Radiosensitizes Pancreatic Cancer but Radioprotects Normal Tissue: The Role of Oxidative Stress-Induced Lipid Peroxidation. Co-author DOI 10.3390/antiox13030361↗
  3. Pharmacologic Ascorbate and DNMT Inhibitors Increase DUOX Expression and Peroxide-Mediated Toxicity in Pancreatic Cancer. Co-author DOI 10.3390/antiox12091683↗
  4. Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002086↗
  5. Auranofin and Pharmacologic Ascorbate as Radiomodulators in the Treatment of Pancreatic Cancer. Co-author DOI 10.3390/antiox11050971↗
  6. Catalase Modulates the Radio-Sensitization of Pancreatic Cancer Cells by Pharmacological Ascorbate. Co-author DOI 10.3390/antiox10040614↗
  7. Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism. Co-author DOI 10.1038/s41598-020-74806-2↗
  8. Arachidonate 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid contribute to stromal aging-induced progression of pancreatic cancer. Co-author DOI 10.1074/jbc.ra120.012798↗
  9. Pharmacologic Ascorbate Primes Pancreatic Cancer Cells for Death by Rewiring Cellular Energetics and Inducing DNA Damage. Co-author DOI 10.1158/1541-7786.mcr-19-0381↗
  10. Enhanced Pharmacological Ascorbate Oxidation Radiosensitizes Pancreatic Cancer. Co-author DOI 10.1667/rr15189.1↗
  11. Pharmacologic ascorbate (P-AscH-) suppresses hypoxia-inducible Factor-1α (HIF-1α) in pancreatic adenocarcinoma. Co-author DOI 10.1007/s10585-018-9876-z↗
  12. Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-1680↗
  13. A model for the detection of pancreatic ductal adenocarcinoma circulating tumor cells. Co-author DOI 10.14440/jbm.2018.250↗
  14. Targeting NAD(P)H:Quinone Oxidoreductase (NQO1) in Pancreatic Cancer. Co-author DOI 10.1002/mc.20199↗
  15. Manganoporphyrins and ascorbate enhance gemcitabine cytotoxicity in pancreatic cancer. Co-author DOI 10.1016/j.freeradbiomed.2015.02.018↗
  16. Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-14-1707↗
  17. Extracellular superoxide dismutase suppresses hypoxia-inducible factor-1α in pancreatic cancer. Co-author DOI 10.1016/j.freeradbiomed.2014.02.002↗
  18. Regulation of pancreatic cancer growth by superoxide. Co-author DOI 10.1002/mc.21891↗
  19. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Co-author DOI 10.1007/s00280-013-2070-8↗
  20. Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer. Co-author DOI 10.1016/j.redox.2013.11.005↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph J. Cullen · 19 shared papers, 2013–2024 · strength 1.91
  2. Brianne R. O’Leary · 11 shared papers, 2018–2024 · strength 1.50
  3. Garry R. Buettner · 14 shared papers, 2013–2024 · strength 1.30
  4. Garett J. Steers · 5 shared papers, 2021–2024 · strength 0.92
  5. Matthew S. Alexander · 6 shared papers, 2018–2020 · strength 0.58
  6. Gloria Y. Chen · 2 shared papers, 2022–2024 · strength 0.43
  7. Prabhat C. Goswami · 4 shared papers, 2014–2023 · strength 0.38
  8. Justin G. Wilkes · 3 shared papers, 2018–2019 · strength 0.24
  9. Ehab H. Sarsour · 2 shared papers, 2019–2020 · strength 0.21
  10. Jianling Bi · 1 shared paper, 2025 · strength 0.19
  11. James D. Byrne · 1 shared paper, 2025 · strength 0.19
  12. Carlos H.F. Chan · 1 shared paper, 2025 · strength 0.19
  13. Zita A. Sibenaller · 3 shared papers, 2014–2018 · strength 0.16
  14. John A. Cieslak · 3 shared papers, 2014–2015 · strength 0.13
  15. Susan Tsai · 2 shared papers, 2015–2018 · strength 0.12
  16. Ming‐Sound Tsao · 2 shared papers, 2013–2017 · strength 0.12
  17. Jessemae L. Welsh · 3 shared papers, 2013–2015 · strength 0.11
  18. Douglas Robert Spitz · 2 shared papers, 2015–2018 · strength 0.11
  19. Bryan G. Allen · 2 shared papers, 2015–2018 · strength 0.11
  20. Daniel Berg · 2 shared papers, 2013–2018 · strength 0.10
  21. Kellie L. Bodeker · 2 shared papers, 2013–2018 · strength 0.10
  22. Visarut Buranasudja · 1 shared paper, 2019 · strength 0.10
  23. Rosa F. Hwang · 1 shared paper, 2019 · strength 0.09
  24. Anne Marie Lewis · 1 shared paper, 2017 · strength 0.08
  25. Justin C. Moser · 2 shared papers, 2013 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.